Announcement PDF ASX/NASDAQ Announcement 11 November 2025 2025 Annual General Meeting Results In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders of the Company passed all resolutions in the Notice of Meeting at the 2025 Annual General Meeting held earlier today. All resolutions put to the meeting were carried by way of a poll. All resolutions were carried. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary. - - - END - - - This release has been authorised by the Directors of Immuron Limited. Further information Steven Lydeamore Chief Executive Officer steve@immuron.com About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper- immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce. For more information visit: https://www.immuron.com.au/ and https://www.travelan.com Sign up to Immuron’s Investor Hub: Here FORWARD-LOOKING STATEMENTS: This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law. Disclosure of Proxy Votes Immuron Limited Annual General Meeting Tuesday, 11 November 2025 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Proxy Votes Poll Results (if applicable) Results Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed FOR AGAINST ABSTAIN PROXY'S DISCRETION FOR AGAINST ABSTAIN OUTCOME 1 Adoption of Remuneration Report P 18,311,580 14,185,764 77.47% 3,938,845 21.51% 1,420,323 186,971 1.02% 14,372,735 78.49% 3,938,845 21.51% 1,420,323 - 2 Re-election of Director - Prof Ravi Savarirayan P 20,752,023 19,089,874 91.99% 1,495,178 7.20% 350,380 166,971 0.80% 19,256,845 92.80% 1,495,178 7.20% 350,380 Carried 3 Re-election of Director - Mr Paul Brennan P 20,762,563 17,205,174 82.87% 3,390,418 16.33% 339,840 166,971 0.80% 17,372,145 83.67% 3,390,418 16.33% 339,840 Carried 4 Approval of increased placement capacity P 21,069,163 18,826,994 89.36% 1,925,198 9.14% 33,240 316,971 1.50% 19,143,965 90.86% 1,925,198 9.14% 33,240 Carried 5 Approval of the Issue of Options to Dr Jeannette Joughin P 20,953,763 16,691,284 79.66% 4,075,508 19.45% 148,640 186,971 0.89% 16,878,255 80.55% 4,075,508 19.45% 148,640 Carried 6 Approval of the Issue of Options to Mr Daniel Pollock P 19,545,013 16,268,454 83.24% 3,089,588 15.81% 988,640 186,971 0.96% 16,455,425 84.19% 3,089,588 15.81% 988,640 Carried 7 Approval of the Issue of Options to Prof Ravi Savarirayan P 20,485,013 16,217,254 79.17% 4,080,788 19.92% 148,640 186,971 0.91% 16,404,225 80.08% 4,080,788 19.92% 148,640 Carried 8 Approval of the Issue of Options to Mr Paul Brennan P 20,953,763 16,879,697 80.56% 3,887,095 18.55% 148,640 186,971 0.89% 17,066,668 81.45% 3,887,095 18.55% 148,640 Carried Proxy Votes Poll Results (if applicable) Results Resolution Decided by Show of Hands (S) or Poll (P) Total Number of Proxy Votes exercisable by proxies validly appointed FOR AGAINST ABSTAIN PROXY'S DISCRETION FOR AGAINST ABSTAIN OUTCOME 9 Ratification of prior issue of shares – Listing Rule 7.1 P 20,872,163 18,865,858 90.39% 1,689,334 8.09% 230,240 316,971 1.52% 19,182,829 91.91% 1,689,334 8.09% 230,240 Carried 10 Ratification of prior issue of shares – Listing Rule 7.1A P 20,724,163 18,697,258 90.22% 1,709,934 8.25% 378,240 316,971 1.53% 19,014,229 91.75% 1,709,934 8.25% 378,240 Carried 11 Approval to renew Proportional Takeover Bid P 21,082,606 18,797,134 89.16% 2,092,978 9.93% 19,797 192,494 0.91% 18,989,628 90.07% 2,092,978 9.93% 19,797 Carried